| Hematologic Diseases |
NCT02480634: Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 4 | 280 | NA | Zoledronic acid, Zometa, Radiotherapy | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non-small Cell Lung Cancer, Bone Metastasis | 09/21 | 12/22 | | |
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase) |
|
|
| Active, not recruiting | 3 | 90 | Japan, US, Europe, RoW | Nilotinib, Imatinib | Novartis Pharmaceuticals | Myelogenous Leukemia, Chronic | 10/18 | 10/18 | | |
|
FAST, NCT02611973: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia |
|
|
| Recruiting | 3 | 2250 | Europe | Aspirin therapy interruption, Usual treatment by aspirin 100 mg/d in the active comparator arm, No interruption of aspirin in the Observational arm, Hydroxyurea treatment (HU) | Assistance Publique - Hôpitaux de Paris | MPN, Essential Thrombocythemia | 11/19 | 11/22 | | |
| Active, not recruiting | 3 | 4420 | Europe | Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) | University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen | Multiple Myeloma | 12/21 | 12/22 | | |
|
|
| Recruiting | 2/3 | 116 | Europe | Eltrombopag, Experimental arm, Placebo (for Eltrombopag), control | B. Höchsmann | Anemia, Aplastic | 09/22 | 09/23 | | |
NCT00850317: Fanconi Anemia Transplant Lacking Genotypically Identical Donor |
|
|
| Not yet recruiting | 2 | 25 | US | Miltenyi CliniMACs device | Children's Hospital Boston, Dana-Farber Cancer Institute | Fanconi Anemia | 04/12 | | | |
NCT02231476: Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients |
|
|
| Recruiting | 2 | 60 | RoW | Zoledronic acid, Zolenic, Zometa | Severance Hospital | Bone Metastasis, Gastrointestinal Cancer | 01/16 | 01/16 | | |
tDCS/PES_SCD, NCT02813629: tDCS Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease |
|
|
| Recruiting | 2 | 120 | RoW | tDCS plus PES, transcranial direct current stimulation (tDCS), peripheral electrical stimulation (PES) | Faculdade Adventista da Bahia, Federal University of Bahia | Anemia, Sickle Cell, Chronic Pain | 12/22 | 12/22 | | |
NCT02188706: A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) |
|
|
| Active, not recruiting | 2 | 120 | US | Decitabine, Dacogen, Carboplatin, Paraplatin, Arsenic Trioxide, ATO, Trisenox | M.D. Anderson Cancer Center, TEVA, Leukemia SPORE | Leukemia | 07/26 | 07/26 | | |
NCT00005846: Tipifarnib in Treating Patients With Myeloproliferative Disorders |
|
|
| Active, not recruiting | 1/2 | | US | tipifarnib | Stanford University, National Cancer Institute (NCI) | Leukemia, Myelodysplastic/Myeloproliferative Neoplasms | | | | |
NCT01754402: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma |
|
|
| Active, not recruiting | 1/2 | 56 | US | Bendamustine, Treanda, Bendeka, Pomalidomide, CC-4047, Pomalyst, Dexamethasone | Cristina Gasparetto, Celgene | Multiple Myeloma | 12/16 | 01/25 | | |
TMI-ASCT, NCT00800059: Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma |
|
|
| Recruiting | 1/2 | 27 | Canada | Total Marrow Irradiation, TMI | Ottawa Hospital Research Institute | Multiple Myeloma | 11/20 | 11/25 | | |
NCT01930253: Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation |
|
|
| | 1 | 5 | US | Bortezomib, Velcade | Children's Hospital Medical Center, Cincinnati | Refractory Autoimmune Cytopenia(s) | 01/14 | 01/14 | | |
NCT00960050: Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone |
|
|
| Active, not recruiting | 1 | 173 | US | polymorphism analysis, laboratory biomarker analysis, medical chart review, assessment of therapy complications | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Leukemia, Lymphoma, Methemoglobinemia, Nonmalignant Neoplasm | 05/15 | | | |
| No Longer Available | N/A | | US, Canada, Europe, RoW | AMN107 | Novartis Pharmaceuticals | Chronic Myeloid Leukemia | 11/08 | | | |
NCT00854841: The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder |
|
|
| Available | N/A | | RoW | Dasatinib and Imatinib, Sprycel and Gliveec | Pusan National University Hospital | Chronic Myeloid Leukemia | | | | |
NCT01250808: Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy |
|
|
| Available | N/A | | RoW | Bortezomib/Dexamethasone/Melphalan | Peking University | Multiple Myeloma | | | | |
NCT01892202: A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis |
|
|
| No Longer Available | N/A | | RoW | Cohort | Hoffmann-La Roche | Anemia | 02/11 | 02/11 | | |
NCT00413270: Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant |
|
|
| No Longer Available | N/A | | Canada | nilotinib | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia | | | | |
NCT01026376: An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) |
|
|
| No Longer Available | N/A | | RoW | decitabine | Janssen-Cilag Farmaceutica Ltda., Janssen Korea, Ltd., Korea | Myelodysplastic Syndromes | 11/11 | 11/11 | | |
| No Longer Available | N/A | | US | Ponatinib, AP24534 | OHSU Knight Cancer Institute, Ariad Pharmaceuticals | Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia | | | | |
NCT01701947: HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency |
|
|
| No Longer Available | N/A | | US | Hemoleven, Human Coagulation Factor XI | Laboratoire français de Fractionnement et de Biotechnologies | Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery | | | | |
NCT01995305: Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents |
|
|
| Available | N/A | | RoW | human whole exome, whole genomic, whole exome | Xiaofan Zhu | Fanconi Anemia, Autosomal or Sex Linked Recessive Genetic Disease, Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases., Hematopoiesis Maintainance. | | | | |
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
|
|
| No Longer Available | N/A | | US | Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis | 01/15 | 01/15 | | |
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. |
|
|
| No Longer Available | N/A | | US | Plerixafor, AMD3100, Mozobil | Genzyme, a Sanofi Company | Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma | | | | |
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib |
|
|
| No Longer Available | N/A | | US | Carfilzomib | University of Arkansas, Onyx Therapeutics, Inc. | Multiple Myeloma | 04/15 | 04/15 | | |
NCT02355782: OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy |
|
|
| Available | N/A | | Europe | OMS721 | Michal Nowicki | Thrombotic Microangiopathy | | | | |
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Elotuzumab, BMS-901608 | Sundar Jagannath, Bristol-Myers Squibb | Multiple Myeloma | | | | |
NCT00799539: A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients |
|
|
| No Longer Available | N/A | | Canada | bortezomib, melphalan, prednisone | Janssen-Ortho Inc., Canada, Ortho Biotech Canada | Multiple Myeloma | | | | |
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Panobinostat | Novartis Pharmaceuticals | Multiple Myeloma | | | | |
NCT02666209: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Ulocuplumab, BMS-936564, Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Decadron | Dana-Farber Cancer Institute, Bristol-Myers Squibb | Multiple Myeloma in Relapse, Multiple Myeloma | | | | |
| Recruiting | N/A | 10 | US | 124I-PU-AD, PET Scan, Blood draws | Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Rockefeller University, Samus Therapeutics, Inc. | Solid Malignancy, Lymphoma, Multiple Myeloma, Alzheimer's Disease | 04/18 | 08/18 | | |
| No Longer Available | N/A | | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Erythrocytosis, Familial, 2 | | | | |
HEMATO-BIO, NCT02320656: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders--IPC-2013-015 |
|
|
| Recruiting | N/A | 650 | Europe | Blood sampling, Bone marrow aspirate, Skin biopsy, Buccal swab | Institut Paoli-Calmettes | Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders | 05/19 | 05/24 | | |
| Recruiting | N/A | 750 | US | | Cystinosis Research Foundation | Cystinosis, Nephropathic Cystinosis, Renal Fanconi Syndrome | 12/20 | 12/22 | | |
| Recruiting | N/A | 500 | RoW | | Hospital Israelita Albert Einstein, Hospital Santa Marcelina, Instituto Nacional de Cancer, Brazil, Federal University of Minas Gerais, Irmandade da Santa Casa de Misericordia de Sao Paulo, Federal University of São Paulo | Hematologic Diseases | 12/22 | 04/25 | | |
CoMMpass, NCT01454297: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile |
|
|
| Completed | N/A | 1154 | Europe, Canada, US | | Multiple Myeloma Research Foundation, Translational Genomics Research Institute, Spectrum Health Hospitals, Van Andel Research Institute | Multiple Myeloma | 11/23 | 12/23 | | |
NCT02330692: Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome |
|
|
| Recruiting | N/A | 1000 | RoW | No intervention | Yonsei University | Myelodysplastic Syndrome | 07/23 | 09/23 | | |
NCT02869256: Regional Central Database Recording of Chronic Myeloid Leukemia |
|
|
| Recruiting | N/A | 400 | Europe | Practices evaluation | Institut Bergonié | Chronic Myeloid Leukemia | 01/24 | 01/24 | | |
NCT02869555: Institut Paoli Calmettes Multiple Myeloma Database |
|
|
| Recruiting | N/A | 5000 | Europe | Data collection | Institut Paoli-Calmettes | Multiple Myeloma | 01/30 | 12/30 | | |
NCT01821456: Cologne Cohort of Neutropenic Patients (CoCoNut) |
|
|
| Recruiting | N/A | 100000 | Europe | Antiinfectives, Antifungals, Antibacterials, Antivirals | University Hospital of Cologne | Hematological Malignancies, Cancer, Chemotherapy, Neutropenia, Immunosuppression | 12/50 | 12/50 | | |